4/A: Processa Pharma Officer Corrects Stock Ownership

Processa Pharmaceuticals' Chief Business Strategy Officer, Patrick Lin, filed an amendment to retract a previously erroneous Form 4 regarding his beneficial ownership of common stock.

Summary

• Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, Inc. (PCSA), filed a Form 4/A to retract a prior Form 4 that was filed in error.
• The amendment clarifies his beneficial ownership of Processa Pharmaceuticals common stock.
• Mr. Lin directly owns 38,727 shares of common stock.
• He indirectly owns 43,500 shares of common stock through the Lin Family Trust.

Sentiment

Score: 5

Explanation: This filing is a routine amendment to correct a previous reporting error regarding insider stock ownership and does not reflect on the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine compliance document for insider trading reporting, specific to an individual officer's stock ownership, and does not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides accurate and updated information regarding insider beneficial ownership, enhancing transparency.

Key Dates

Recommendation

The filing solely addresses a correction to an insider ownership report and offers no insights into the company's financial performance, strategic initiatives, or operational outlook that would warrant a change in investment recommendation.

Keywords

Processa Pharmaceuticals, PCSA, Form 4/A, Beneficial Ownership, Insider Trading, Patrick Lin, Chief Business Strategy Officer, Common Stock